Opinion: Market share isn’t the only metric for biosimilars’ success
Market share is often held up as the most relevant metric for the success of a biosimilar class. I believe there are other metrics, like cost savings or signs of …
Read MoreTag: drug pricing
With a promising new plan to pay for pricey cures, two states set out to eliminate hepatitis C. But cost hasn’t been the biggest problem
WASHINGTON — For nearly a decade, many experts assumed the biggest obstacle to eliminating hepatitis C was the sky-high cost of the new cures. So when Washington state and Louisiana …
Read More
Opinion: Launch prices: tackling the next drug pricing challenge
The passage of the Inflation Reduction Act brings a new era to drug pricing in the United States. After decades of being an outlier, it now joins every other developed …
Read More
Opinion: The Inflation Reduction Act: One step closer to pharmacoequity?
President Biden’s signing of the Inflation Reduction Act on Tuesday marked a health care law that could have the greatest impact since President Obama signed the Affordable Care Act in …
Read More
Opinion: Are ‘modest’ drug price controls as bad for innovation as pharma claims?
Drug price controls proposed by Democrats in the U.S. Senate are being met with dire warnings that such an approach will stifle innovation, shut off the pipeline of new medicines, …
Read More
Opinion: WTO: Don’t make a bad situation worse by granting intellectual property waivers for Covid-19 therapeutics and diagnostics
The World Trade Organization recently agreed to suspend patent protections for Covid-19 vaccines. The trade body is now considering going one step further: extending the intellectual property waiver to Covid-19 …
Read More
Opinion: Drug price controls are a dance with the devil: short-term savings will be overwhelmed by loss of innovation
Democrats have sent the legislative text of a sweeping proposal for drug price controls to the U.S. Senate parliamentarian, who may report on Monday whether the provisions qualify for the …
Read More
Opinion: Hospitals and for-profit PBMs are diverting billions in 340B savings from patients in need
America’s economically disadvantaged patients can point in two directions when talking about what is wrong with the 340B Drug Pricing Program, which is designed to help hospitals caring for underserved …
Read More
Opinion: PBMs are inflating the cost of generic drugs. They must be reined in
These are not comfortable days in Washington for pharmacy benefit managers, the highly consolidated group of intermediaries that sit astride the drug supply chain. The Federal Trade Commission and Capitol …
Read More